Abstract
Biasing G protein-coupled receptor signaling with ligands that promote select pathways is emerging as a powerful approach for therapeutic drug discovery. In this issue of Cell, Slosky etal. report a β-arrestin-biased neurotensin receptor ligand that may curtail drug abuse without the side effects induced by G protein signaling.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have